Suplasyn

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Suplasyn

What is Suplasyn? Overview

Property Description
Active Ingredient Sodium Hyaluronate (Hyaluronan)
Form Sterile Viscoelastic Solution (Intra-articular Injection)
Pharmacological Class Viscosupplementation Agent (Orthopedic Device Class)
General Purpose Joint Function Restoration and Mechanical Support
Origin Bio-fermentation (Endogenous Substance Derivative)

Suplasyn: Definition and Classification

Suplasyn is an injectable, sterile, viscoelastic solution used to physically supplement the functional fluid within diarthrodial joints. It is classified as an advanced Medical Device (Class III) in jurisdictions like the European Economic Area, distinguishing its mechanism from that of traditional drugs. Its primary classification as a Viscosupplementation Agent reflects its non-pharmacological action of providing direct mechanical support and lubrication to the joint capsule. Suplasyn is supplied as a ready-to-use Intra-articular Injection in a pre-filled syringe, and pharmacological studies confirm its necessity for effective viscosity. The product is typically positioned to support patients experiencing reduced joint mobility.


What is Sodium Hyaluronate and Where Does it Come From?

The sole active substance in Suplasyn is Sodium Hyaluronate (INN), a purified salt form of the naturally occurring compound known as Hyaluronan. This substance is classified biochemically as an endogenous polysaccharide and is a vital component of the synovial fluid, where it confers the necessary viscoelasticity and cushioning. To ensure high purity and biocompatibility, the Sodium Hyaluronate used is typically manufactured through controlled microbial bio-fermentation, making it an Endogenous Substance Derivative suitable for injection.


What is the General Purpose of Suplasyn?

The general purpose of Suplasyn is to restore proper physical joint function by supplementing the quality and volume of the degraded synovial fluid. The solution's mechanical properties enable it to simultaneously act as an effective lubricant and a Shock Absorption mechanism within the joint space. This physical replacement action promotes smoother, less restricted movement and provides continuous mechanical support, which helps the joint operate effectively under dynamic load. The benefit is often recognized in typical scenarios where joint function is impaired, such as difficulty rising from a chair or climbing stairs.

Regulatory References

  1. NIH Viscosupplementation Review
  2. NIH Hyaluronan Properties

What side effects are possible with Suplasyn?

Possible side effects and safety information

The official safety profile for Suplasyn (Sodium Hyaluronate) is primarily characterized by adverse events related to the intra-articular injection procedure itself, with the most frequent reactions being local and temporary. Regulatory documents classify and detail these effects across different system-organ classes.

Frequency-Classified Adverse Reactions

The majority of documented effects are classified by the regulatory authorities as transient or short-duration. Mild local reactions, which may include pain, a feeling of heat, redness, swelling, or irritation at the injection site, are commonly observed. These symptoms are expected to subside, typically within days, for most patients. Systemic reactions, such as fever and chills, are documented in rare cases.

Classification Tier Documented Reactions
Rare Fever, chills, cardiovascular reactions
Extremely Rare Anaphylactic reactions, rash, urticaria, drop in blood pressure

Serious Adverse Reactions and Systemic Events

While highly uncommon, the regulatory label documents the potential for serious adverse reactions. This includes anaphylactic reactions, which are severe systemic allergic events. The label also documents significantly enhanced and more severe local reactions, which are classified as expressions of hypersensitivity and may necessitate therapeutic intervention.

Adverse events are classified under the System-Organ Classes (SOC) including General disorders and administration site conditions and Immune System Disorders.

Safety-Related Restrictions and Considerations

The official safety documents specify conditions and populations where the product should not be used or is not recommended:

  • Existing Joint Conditions: The injection should not be administered to patients who present with inflammation, a symptom flare, or significant effusion in the joint. The likelihood of adverse events is noted to be greater in joints that already have existing inflammation or irritation.
  • Hypersensitivity: Use is contraindicated for patients with a known hypersensitivity to the preparation or its components.
  • Specific Populations: Due to the lack of available clinical evidence, treatment is not recommended for use in children or in pregnant and lactating women.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for this class of product confirms that systemic overdosage is unlikely and remains unreported due to its local, intra-articular route of administration and single-use packaging. Consequently, no specific signs or symptoms related to systemic over-administration are officially documented in prescribing information.

Since systemic effects are not anticipated, regulatory guidance on seeking urgent medical help is focused on two main scenarios:

When to seek immediate medical attention

  • Signs of Severe Allergic Reaction: Seek immediate medical attention if you experience signs of a severe systemic allergic event, such as difficulty breathing, swelling of the face, lips, tongue, or throat, or generalized hives.
  • Severe Local Adverse Reaction: Contact a healthcare provider immediately if you experience severe, persistent pain or marked swelling around the injection site that does not quickly subside.

Supportive Measures

Measure Official Documentation
Antidote No specific systemic antidote is known or documented.
Local Support For common, transient local reactions like mild pain or swelling, the standard procedure is to rest the affected joint and apply ice locally.

The official documents state that overdosage is not a defined clinical scenario for this product, and emergency actions are strictly mandated for the potential development of severe adverse reactions.

Therapeutic Uses of Suplasyn

What Suplasyn Treats: Main Uses and Benefits

The primary role of Suplasyn is applied across domains where additional symptomatic support is needed in conditions involving episodic or fluctuating manifestations. It is relevant when supportive symptom management is appropriate, as detailed in related clinical overviews for similar therapeutic categories.


Easing Joint Symptom Clusters

Suplasyn is commonly used for managing symptoms related to physical discomfort that often cluster around affected joints. It is relevant in clinical settings that involve acute or unstable symptom patterns, and supports the patient during difficult episodes by easing distress when joint symptoms become more noticeable. This provides support that helps ease the overall symptom burden.

Supporting Relief in Episodic Discomfort

It is often used during phases when symptoms intensify and short-term symptomatic assistance is needed, especially in conditions involving episodic or fluctuating manifestations. Suplasyn is considered relevant for managing symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Stiffness Suplasyn is applied when groups of symptoms, including stiffness, interfere with daily comfort.

Addressing Noticeable Functional Strain

Suplasyn is applied when symptoms create noticeable interference with daily functioning. By assisting with maintenance of functional stability, it is commonly used to help with managing symptoms that create noticeable physiological strain, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. Summary of Safety and Effectiveness Data (SSED) - FDA

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Suplasyn

Regulatory documents define specific populations who are permitted to use Suplasyn (sodium hyaluronate) and those who are formally excluded or for whom use is not established.

Classification Population/Condition Status Restriction Details
Allowed Use Adults (18 years and older) For treatment of pain in osteoarthritis of the knee.
Contraindicated Known Hypersensitivity Patients with known allergy to hyaluronate preparations (and possibly avian proteins, depending on the product source).
Contraindicated Local Conditions Injection is prohibited in a knee with an active infection, severe inflammation/effusion, or skin disease at the injection site.
Use Not Established Children/Adolescents Safety and effectiveness are not established in pediatric patients (under 18 years of age).
Use Not Established Pregnancy/Lactation Safety and effectiveness have not been established for pregnant or breastfeeding women. Use is not recommended in these patients.
Conditional Use Inflammatory Arthritis Caution is required, and the treating physician must evaluate whether to initiate treatment in patients with inflammatory arthritis (e.g., rheumatoid arthritis or gouty arthritis).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Suplasyn (Sodium Hyaluronate) is defined by local procedural and chemical constraints, consistent with its classification as a local-acting viscosupplementation solution. As its action is confined to the joint space and it is not a systemically absorbed drug, documented interactions are focused on local incompatibilities rather than metabolic drug-drug interactions.


Documented Interaction Patterns

Interaction Type Interacting Product / Substance Regulatory Restriction
Local Chemical Incompatibility Disinfectants containing quaternary ammonium salts Concomitant use is prohibited because the official regulatory documentation states that the hyaluronic acid solution can precipitate upon contact.
Local Co-Administration Other intra-articular injectables Simultaneous administration or mixing is restricted as the safety and effectiveness of using the product concomitantly with other intra-articular injections have not been established.

Systemic Interaction Status

Official regulatory sources do not document any systemic drug-drug interactions, including those mediated by Cytochrome P450 enzymes (metabolic interactions) or drug transporters. Similarly, no interactions with food, alcohol, or herbal products are specified in the official prescribing information. The interaction profile is exclusively restricted to the procedural setting and the immediate site of administration.

Mechanism of Action

Suplasyn, a formulation of hyaluronic acid (HA), is administered into the synovial space, where it selectively accumulates within the joint tissue, including the synovial fluid and articular cartilage.

Its mechanical mechanism involves increasing the viscoelasticity of the synovial fluid, restoring the rheological and tribological properties of the lubricating layer. This modulation results in a reduction of interfacial friction and shear strain across the articulating cartilage surfaces.

Biologically, the HA molecule interacts with cell-surface receptors on target cells, specifically chondrocytes and synoviocytes. Binding to receptors, such as CD44, mediates intracellular signaling cascades. This interaction downregulates the expression of pro-inflammatory cytokines, including interleukin-1 beta (IL-1beta), which consequentially decreases the activity of matrix metalloproteinases (MMPs). The reduced MMP activity leads to a decrease in the rate of extracellular matrix (ECM) catabolism within the cartilage. Furthermore, the molecular interaction facilitates the proliferation of endogenous HA synthesis and proteoglycan synthesis by chondrocytes, contributing to the structural integrity and homeostatic modulation of the joint's ECM.

Dosage and Administration Information

The administration of Suplasyn is governed by a strict protocol aligned with its formulation as a sterile, intra-articular medical device and must be executed by a physician. The overall method of use is structured around the injection route, specific dosing volumes, and required procedural constraints.

Official Administration Guidelines

Instruction Detail
Route of Administration Intra-articular Injection (IA). The solution must be administered directly into the synovial space of the affected joint.
Dosing Schedule Suplasyn (2 mL): Up to 2 mL administered per joint. Suplasyn 1-Shot (6 mL): A single 6 mL dose for large joints. Suplasyn m.d. (0.7 mL): Up to 0.7 mL for small synovial joints.
Frequency Pattern Weekly for multi-dose formats (e.g., typically one injection per week for three weeks). The single-shot format is administered once.
Course Repetition A full course of treatment may be repeated after an interval of not less than six months from the prior course.

Procedural and Contextual Requirements

The product is supplied in a pre-filled, ready-to-use syringe and must be warmed to room temperature before administration. Strict aseptic technique must be observed by the physician throughout the procedure to maintain sterility. If joint effusion (excess fluid) is present, it should be aspirated prior to injecting the solution, and any unused portion of the syringe must be discarded after administration, as it is intended for single use only. Patients are advised to rest the treated joint for 24–48 hours following the injection and to avoid strenuous activity during the entire course of treatment. Regarding specific populations, no adjustment of dose is required for older adults.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evidence Summary

Clinical research has evaluated whether the intra-articular injection of hyaluronic acid (the active ingredient in Suplasyn) is associated with changes in joint function and pain intensity in individuals with osteoarthritis of the knee. Viscosupplementation, the process of injecting a fluid to potentially restore the viscoelastic properties of synovial fluid, has been investigated as a treatment option for symptomatic knee osteoarthritis, particularly in patients who have not found adequate relief from non-pharmacological and other standard pharmacological therapies.

Evidence from meta-analyses suggests that hyaluronic acid injections are associated with a small reduction in pain and improvements in joint function compared to placebo, though some analyses indicate this difference may be less than the minimum considered clinically important. The reported benefits often exhibit a slower onset compared to corticosteroids but may persist for a longer duration, potentially up to six months following treatment.


Key Study Observations

Research typically focuses on outcomes measured by standard instruments like the Western Ontario and McMaster Universities Arthritis Index (WOMAC) and the Visual Analogue Scale (VAS).

  • Pain and Function: Studies examined whether differences in pain intensity and functional ability scores were observed in treated groups compared to control groups over periods of several weeks to months. The data gathered suggests an association with improved mobility scores.
  • Duration of Observation: While short-term efficacy is frequently evaluated, investigation of longer-term exposure (beyond six months) has been conducted in specific cohorts, but the overall evidence base on sustained effects remains limited.

Adverse Events and Safety Profile

The frequency of adverse events associated with hyaluronic acid injections is generally considered low. Adverse events are typically localized and temporary.

  • Local Reactions: The most frequently reported adverse events in studies involve temporary local pain, swelling, or warmth at the injection site, often resolving within a few days.
  • Systemic Risk: Limited evidence exists from short-term trials on potential systemic safety concerns. Research has also explored the potential risks of co-administration with other treatments.
  • Dosing Studied: The dose and regimen evaluated in studies vary by formulation, commonly involving one or a series of injections.

Key Studies & References

  1. Efficacy and safety of hyaluronic acid and its derivatives as therapy in osteoarthritis of the knee: a meta-analysis.
  2. NICE Guideline: Osteoarthritis: care and management.
  3. Clinical Effectiveness of Viscosupplementation for Knee Osteoarthritis: A Systematic Review.

Frequently Asked Questions (FAQ)

Common questions about Suplasyn (FAQ)


Q: How quickly does Suplasyn start working after the injection?

Clinical evidence for viscosupplementation agents often suggests a slower onset of pain relief compared to traditional steroid injections. While the exact time frame for noticeable pain relief varies, a precise time in hours or days for the onset of effect is not consistently defined in the core regulatory documents.


Q: How long do the pain-relieving effects of a Suplasyn injection last?

Studies and official information indicate that the benefits of a full course of treatment may persist for a longer duration compared to other joint therapies, potentially lasting up to six months. A full course of treatment may be repeated after an interval, as determined by a healthcare provider.


Q: Can Suplasyn injections be used in joints other than the knee, like the hip or shoulder?

The official regulatory indication for Suplasyn is specifically for the symptomatic treatment of pain associated with osteoarthritis of the knee. Safety and effectiveness for use in other joints, such as the hip or shoulder, have not been established in the core regulatory documents.


Q: Why might a doctor stop recommending Suplasyn for a patient?

Discontinuation may be necessary under certain conditions, as outlined in the official warnings. This includes the presence of severe adverse reactions or if the joint develops active inflammation or infection, which are generally conditions that contraindicate the use of the product.


Q: What kind of research supports the use of Suplasyn for osteoarthritis?

Clinical research supports the use of hyaluronic acid preparations in symptomatic knee osteoarthritis. Studies indicate an association with a small reduction in pain and improvements in functional ability scores, often measured by standard instruments such as the WOMAC index.


Q: Can you exercise right after a Suplasyn injection?

Patients are generally advised in the official guidelines to rest the treated joint for 24 to 48 hours following the injection. Additionally, strenuous activity is generally advised to be avoided during the entire course of treatment.


Q: What should I avoid doing right before a Suplasyn treatment?

The official product documentation states that the skin disinfectant used for preparation should not contain quaternary ammonium salts. These chemicals are locally incompatible with the hyaluronic acid solution and can cause it to precipitate.


Q: Does Suplasyn interact with common over-the-counter pain medications like ibuprofen?

Regulatory sources do not document systemic drug-drug interactions with common over-the-counter or prescription medications. Documented incompatibilities are strictly local and procedural.


Q: Do people typically need to take time off work after a Suplasyn injection?

Official patient guidance recommends resting the treated joint for 24 to 48 hours after the injection and avoiding strenuous activity. The impact on work depends on the physical demands of the patient's occupation.


Q: Can Suplasyn cause an allergic reaction?

Yes, local reactions at the injection site, such as redness or excessive swelling, may be expressions of a hypersensitivity reaction. Severe systemic allergic events, including anaphylactic reactions, are documented in the regulatory safety profile as extremely rare occurrences.


Q: Are there any long-term side effects associated with multiple Suplasyn injections?

Evidence on safety and effectiveness is primarily based on clinical studies of shorter duration, typically up to six months. Official documents note that the full long-term safety profile beyond this period has not been established.


Q: Can Suplasyn be used for post-traumatic arthritis?

The official therapeutic indication approved by regulatory bodies is for the symptomatic treatment of pain in osteoarthritis of the knee. Other specific forms of arthritis are not explicitly covered by the approved indication.


Q: Why do some doctors recommend a series of Suplasyn shots while others suggest just one?

The product is manufactured and supplied in different formulations. Official dosing schedules include both a multi-dose format (which requires a series of injections) and a single-shot format. The choice between these depends on the specific product being used and is determined by the healthcare provider.


Q: Is there an age limit for who can receive Suplasyn?

The product is indicated for use in adults, specifically those 18 years and older. Safety and effectiveness have not been established in pediatric patients, including children and adolescents.


Q: What is the mechanism by which Suplasyn improves joint movement?

Suplasyn improves joint function and movement by supplementing the joint fluid. This restores the fluid’s natural viscoelasticity, which provides lubrication and acts as a shock absorber within the joint space.


Q: How should I store Suplasyn if I have the pre-filled syringes at home?

The product's integrity requires storage below 25 C (77 F), with freezing explicitly forbidden. It must also be kept in the original packaging to protect the syringe from light and physical damage.


Q: What should I do if the post-injection swelling doesn't go away after a few days?

While mild local symptoms are usually expected to be transient, if symptoms are severe, worsen, or persist past a few days, consultation with a healthcare provider is recommended, as this may indicate a need for evaluation.


Q: Why does Suplasyn require a prescription if it's not a steroid?

Suplasyn is classified as a sterile, intra-articular medical device. Because it must be administered directly into the joint space by a physician using a strict aseptic procedure, it is available only under medical supervision.


Q: Are there any specific supplements that interact negatively with Suplasyn?

The official product information does not document any systemic interactions with food, alcohol, herbal products, or supplements. Documented incompatibilities are strictly local and procedural.


Q: Can Suplasyn be used to treat rheumatoid arthritis?

The official indication is for osteoarthritis. Use in patients with inflammatory joint disease, such as rheumatoid arthritis, is noted in regulatory documents as requiring caution.


Q: Is it necessary to ice the joint after the Suplasyn shot?

Official guidance notes that if mild local reactions occur (such as pain or swelling), resting the joint and applying ice locally may be helpful to manage these temporary symptoms.

How should Suplasyn be stored and disposed of?

How to Store and Dispose of Suplasyn?

The storage and disposal requirements for Suplasyn are defined by regulatory labeling to ensure the product's integrity and sterility until the point of use.

Official Storage Conditions

Requirement Specific Rule
Temperature Store below 25 C (77 F).
Freezing Do not freeze the product under any circumstances.
Protection Keep in the original packaging to protect the syringe from light and physical damage.

Handling and Disposal Rules

Suplasyn is supplied as a sterile, single-use product. The official label mandates strict container integrity rules: the pre-filled syringe must not be used if the package is opened or damaged, or if the syringe itself has cracks or breakage. The product is for single use only, meaning any unused portion of the solution remaining in the syringe after initial use must be discarded immediately. Do not use the product after the expiration date printed on the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Suplasyn found in:

A-Z Index: